9 years of historical data (2016–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Inhibrx Biosciences, Inc. trades at 0.6x earnings, 381% above its 5-year average of 0.1x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 97%.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.1B | $223M | $1.8B | $988M | $1.7B | $833M | — | — | — | — |
| Enterprise Value | $930M | $78M | $1.7B | $921M | $1.6B | $742M | — | — | — | — |
| P/E Ratio → | 0.64 | 0.13 | — | — | — | — | — | — | — | — |
| P/S Ratio | 5373.68 | 1114.64 | 994.97 | 450.85 | 232.97 | 65.03 | — | — | — | — |
| P/B Ratio | 8.03 | 1.67 | 41.17 | 17.02 | 31.69 | 11.04 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 391.90 | 957.31 | 420.39 | 224.67 | 57.90 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | 0.05 | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Inhibrx Biosciences, Inc. earns an operating margin of -165724.0%. Operating margins have compressed from -5890.4% to -165724.0% over the past 3 years, signaling potential cost pressures or competitive headwinds. Return on equity of 1905.9% is exceptionally high, though this is partly amplified by negative book value driven by aggressive share buybacks.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -1042.5% | -1042.5% | 33.8% | -4926.7% | 62.3% | -473.8% | -426.9% | -346.1% | -220.9% | -154.9% |
| Operating Margin | -165724.0% | -165724.0% | -12178.9% | -5890.4% | -1074.6% | -526.6% | -480.7% | -393.5% | -248.2% | -182.2% |
| Net Profit Margin | 843786.0% | 843786.0% | -13408.9% | -6625.3% | -1147.6% | -590.5% | -565.3% | -415.5% | -244.6% | -124.0% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 1905.9% | 1905.9% | -475.3% | -263.0% | -127.9% | -100.2% | — | — | — | -667.4% |
| ROA | 690.7% | 690.7% | -80.6% | -65.8% | -55.6% | -88.9% | -281.9% | -228.9% | -101.0% | -38.9% |
| ROIC | — | — | — | — | — | — | — | — | — | -6901.1% |
| ROCE | -169.3% | -169.3% | -85.2% | -66.0% | -63.7% | -114.1% | -738.5% | -2773.8% | -162.3% | -76.0% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $153M exceeds total debt of $8M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 4.83 | 3.57 | 1.38 | 0.50 | — | — | — | 15.27 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.08 | -1.56 | -1.15 | -1.13 | -1.21 | — | — | — | -0.89 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -24.57 | -24.57 | -6.89 | -8.02 | -14.68 | -6.24 | -7.64 | -19.94 | -9.28 | — |
Net cash position: cash ($153M) exceeds total debt ($8M)
Short-term solvency ratios and asset-utilisation metrics
Inhibrx Biosciences, Inc.'s current ratio of 3.94x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 10.17x to 3.94x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.94 | 3.94 | 5.25 | 10.17 | 6.20 | 4.21 | 0.76 | 0.35 | 1.73 | 3.87 |
| Quick Ratio | 3.94 | 3.94 | 5.25 | 10.17 | 6.23 | 8.33 | 0.60 | 0.21 | 1.62 | 3.87 |
| Cash Ratio | 3.75 | 3.75 | 4.94 | 9.93 | 5.85 | 4.10 | 0.56 | 0.13 | 1.51 | 3.79 |
| Asset Turnover | — | 0.00 | 0.01 | 0.01 | 0.05 | 0.09 | 0.34 | 0.75 | 0.46 | 0.31 |
| Inventory Turnover | 14.94 | — | — | — | — | — | 14.94 | 14.48 | 25.54 | — |
| Days Sales Outstanding | — | 766.50 | 157.76 | 42.79 | 44.98 | 17.53 | 17.58 | 33.58 | 31.95 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Inhibrx Biosciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 100.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 100.0% | 757.0% | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $14M | $47M | $40M | $38M | $25M | $37M | $27M | $29M | $37M |
Compare INBX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| INBXYou | $1B | 0.6 | — | — | -1042.5% | -165724.0% | 1905.9% | — | — |
| RVMD | $20B | -17.1 | — | — | — | — | -58.1% | -54.3% | — |
| INCY | $20B | 15.8 | 11.9 | 14.8 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
| GMAB | $18B | 15.4 | 14.9 | 15.1 | 95.4% | 31.1% | 23.0% | 22.2% | 0.1 |
| EXEL | $12B | 15.8 | 13.2 | 13.4 | — | 37.6% | 35.5% | 32.1% | 0.2 |
| IBRX | $10B | -15.8 | — | — | 100.0% | -2334.2% | — | — | — |
| MRUS | $7B | -26.9 | — | — | 37.2% | -753.0% | -41.4% | -74.6% | — |
| CELC | $5B | -39.5 | — | — | — | — | -87.5% | -50.3% | — |
| CGON | $5B | -41.7 | — | — | 100.0% | -10067.3% | -19.2% | -26.3% | — |
| ERAS | $4B | -19.8 | — | — | — | — | -43.7% | -39.2% | — |
| IDYA | $3B | -25.2 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 9 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how INBX stacks up against sector leader Revolution Medicines, Inc..
Start ComparisonInhibrx Biosciences, Inc.'s current P/E ratio is 0.6x. The historical average is 0.1x. This places it at the 100th percentile of its historical range.
Inhibrx Biosciences, Inc.'s return on equity (ROE) is 1905.9%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -241.6%.
Based on historical data, Inhibrx Biosciences, Inc. is trading at a P/E of 0.6x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Inhibrx Biosciences, Inc. has -1042.5% gross margin and -165724.0% operating margin.